Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MLATO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
hL49-ADC
|
|||||
| Synonyms |
hL49 ADC
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Humanized Anti-CD228 SGN-CD228A mAb
|
Antibody Info | ||||
| Antigen Name |
Melanotransferrin (MELTF)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
mp-dLAE-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 32% | Low CD228 expression (CD228+) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 72% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | IGR-37 cells | CVCL_2075 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 78% | Moderate CD228 expression (CD228++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | A2058 cells | CVCL_1059 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 79% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-28 cells | CVCL_0526 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 80% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Maximum inhibition efficiency (MIE) | 86% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2 nM | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3 nM | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-28 cells | CVCL_0526 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4 nM | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 21 nM | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | IGR-37 cells | CVCL_2075 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 31 nM | Moderate CD228 expression (CD228++) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Melanoma | A2058 cells | CVCL_1059 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 2000 nM | Low CD228 expression (CD228+) | ||
| Method Description |
Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||